Rheumatology Advance Access published online on April 6, 2005
Rheumatology, doi:10.1093/rheumatology/keh624
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 University College London, London, UK
* To whom correspondence should be addressed. Objective. To devise a more discriminating version of the British Isles Lupus Assessment Group (BILAG) disease activity index and to show that it is reliable. Methods. A nominal consensus approach was undertaken by members of BILAG to update and improve the BILAG lupus disease activity index. The index has been revised following intense consultations over a 1-yr period. It has been assessed in two real-patient exercises. These involved patients with diverse clinical features of SLE, including gastrointestinal, hepatic and ophthalmic problems, which the earlier versions of the index did not fully take into account. Reliability in terms of the ability to differentiate patients was assessed by calculating intraclass correlation coefficients. The level of agreement between physicians was determined by calculating the ratio of estimates of the standard error (SE) attributable to the physicians to the SE attributable to the patients. Results. Good reliability and high levels of physician agreement were observed in one or both exercises in the constitutional, mucocutaneous, neurological, cardiorespiratory, renal, ophthalmic and haematological systems. In contrast, the musculoskeletal system did not score as well, although providing more clear-cut glossary definitions should greatly improve the situation. Conclusions. Some significant changes in the BILAG disease activity index to assess patients with SLE are proposed. The process of demonstrating validity and reliability has started with these two exercises assessing real patients. Further validation studies are under way. BILAG 2004 is likely to be valuable in clinical trials assessing new therapies for the treatment of SLE, as it provides a more comprehensive system-based disease activity measure than has been available previously.
Received September 8, 2004
Accepted February 25, 2005
Original Papers
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus
2 University of Cambridge, Cambridge, UK
3 Sheffield Centre for Rheumatic Disease, Sheffield, UK
4 University of Manchester, Manchester, UK
5 St Thomas’ Hospital, London, UK
6 The Freeman Hospital, Newcastle, UK
7 University of Wales, Bangor, UK
8 Royal National Hospital for Rheumatic Diseases, Bath, UK
9 Derbyshire Royal Infirmary, Debshire, UK
10 Blackburn Royal Infirmary, Blackburn, UK
11 University of Birmingham, Birmingham, UK
12 Hairmyres Hospital, East Kilbride, Scotland, UK
D. A. Isenberg, E-mail: d.isenberg{at}ucl.ac.uk
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C.-S. Yee, V. Farewell, D. A. Isenberg, B. Griffiths, L.-S. Teh, I. N. Bruce, Y. Ahmad, A. Rahman, A. Prabu, M. Akil, et al. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity Rheumatology, June 1, 2009; 48(6): 691 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Podolskaya, M Stadermann, C Pilkington, S D Marks, and K Tullus B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus Arch. Dis. Child., May 1, 2008; 93(5): 401 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sinclair, G. Appel, M.A. Dooley, E. Ginzler, D. Isenberg, D. Jayne, D. Wofsy, and N. Solomons Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS) Lupus, December 1, 2007; 16(12): 972 - 980. [Abstract] [PDF]
|
|
|
|
|
|
R. R. Sivaraj, O. M. Durrani, A. K. Denniston, P. I. Murray, and C. Gordon Ocular manifestations of systemic lupus erythematosus Rheumatology, December 1, 2007; 46(12): 1757 - 1762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Petri and R. Brodsky High-Dose Cyclophosphamide and Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus JAMA, February 1, 2006; 295(5): 559 - 560. [Full Text] [PDF]
|
|